文献速递慢性静脉疾病

非植入式深静脉瓣膜成形术治疗深静脉反流的安全性与可行性中期报告

Safety and feasibility report on nonimplantable endovenous valve formation for the treatment of deep vein reflux.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2021-01-19

本研究评估BlueLeaf系统在慢性静脉功能不全(CEAP 4-6)患者中形成自体深静脉瓣膜的中期安全性和有效性。

要点

  • BlueLeaf系统可安全形成自体深静脉瓣膜,无深静脉血栓发生
  • 静脉临床严重程度评分显著持续改善,溃疡愈合率较高
  • 反流时间未显著改善,需进一步优化器械设计

核心结论

  • BlueLeaf系统作为微创方法安全形成完全自体深静脉瓣膜具有前景,重建深静脉保持通畅且无深静脉血栓,症状改善一致观察但反流时间未降低。

研究设计与样本

  • 早期可行性研究,纳入14例慢性静脉功能不全(CEAP 4-6)患者,随访至1年,用双功超声评估静脉通畅性和反流时间,用修订版静脉临床严重程度评分评估临床改善。

主要发现

  • 14例患者中13例(93%)成功形成至少一个单瓣叶瓣膜,平均每例1.4个瓣膜(范围0-3个)。
  • 围手术期无器械相关严重不良事件,任何时间点包括10例完成1年随访者均无深静脉血栓报告。
  • 在至少形成一个瓣膜的患者中,瓣膜下方腘静脉平均反流时间基线为3.0±1.0秒,30天为3.9±3.1秒,360天为3.6±2.1秒。
  • 基线有溃疡的5例患者中,达到360天随访者全部(100%)至少愈合一个溃疡,2例(40%)愈合所有溃疡,3例(60%)溃疡数量减少但仍为C6期;基线共9个活动性溃疡在360天时有4个活动性溃疡。

关键数值与推荐

  • 成功形成至少一个单瓣叶瓣膜的比例为93%(13/14)。
  • 平均每例形成1.4个瓣膜(范围0-3个)。
  • 基线有溃疡的5例患者中,达到360天随访者全部(100%)至少愈合一个溃疡。

临床怎么用

  • BlueLeaf系统或可作为症状性深静脉反流的微创治疗选择,避免永久性异物植入相关并发症。
  • 术后需用双功超声监测静脉通畅性和反流时间,并用修订版静脉临床严重程度评分评估临床改善。
  • 目前反流时间未显著改善,器械设计改进后的临床效果有待进一步评估。

局限性

  • 早期可行性研究样本量小(14例),仅10例完成1年随访。
  • 反流时间未显示改善,提示瓣膜功能可能不足。
  • 器械设计已进行迭代改进,但改进后的结果尚待临床评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Definitive treatment techniques for symptomatic deep venous reflux have been relegated to complex and invasive open surgery which is rarely performed today. The BlueLeaf System provides an endovenous method for the formation of deep venous valves without an implant, avoiding the complications associated with permanent foreign materials. The system has the adaptability to form valves within the femoral and popliteal veins at multiple levels in a single procedure. The aim was to determine the midterm safety and efficacy of this novel device in an early feasibility study. METHODS: Feasibility of endovenous deep venous valve formation was assessed in patients with chronic venous insufficiency (Clinical, Etiologic, Anatomic, Pathophysiologic [CEAP] 4-6). Follow-up was completed through 1 year, assessing vein patency and reflux time (RT) with duplex ultrasound examination. Venous clinical improvement was evaluated using the revised Venous Clinical Severity Scale. RESULTS: Of the 14 patients, 13 (93%) had successful formation of at least one monocuspid valve, with a mean number of 1.4 valves (range, 0-3 valves) per patient. There were no device-related serious adverse events during the index procedure. There were no deep venous thromboses reported at any time point, including 10 patients through the 1-year follow-up. In patients with at least one valve formed, site reported duplex ultrasound examination measured the average RT in the popliteal vein below valve formations, was 3.0 ± 1.0 seconds at baseline, 3.9 ± 3.1 seconds at 30 days, and 3.6 ± 2.1 seconds at 360 days. The revised Venous Clinical Severity Scale improved in all 13 successfully treated patients, decreasing from 15.0 ± 6.0 at baseline to 11.6 ± 5.5 at 30 days, 10.7 ± 5.3 at 210 days, and 9.4 ± 5.0 at 360 days (P = .0002; baseline to 360 days). Among the five patients with an ulcer who reached the 360-day follow-up visit, all (100%) healed at least one ulcer. Two patients (40%) healed all ulcers and three patients (60%) had a decrease in ulcers number but remained at C6 at 360 days. The five patients with a total of nine active ulcers at baseline had four active ulcers at 360 days. CONCLUSIONS: The BlueLeaf System holds promise as a minimally invasive means to safely form fully autogenous deep venous valves. Reconstructed deep veins remained patent, without deep venous thrombosis and symptomatic improvement was consistently observed; however, a decrease in the RT was not. Incremental device design improvements have been undertaken to improve valve function. The results of these iterations await further clinical evaluation.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Vasudevan T, Robinson DA, Hill AA, et al. Safety and feasibility report on nonimplantable endovenous valve formation for the treatment of deep vein reflux. J Vasc Surg Venous Lymphat Disord. 2021. PMID: 33359385. doi:10.1016/j.jvsv.2020.12.073

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。